search
Back to results

Epinephrine Sprayed on the Papilla Versus Sterile Water Sprayed on the Papilla for Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography

Primary Purpose

Pancreatitis, Acute

Status
Terminated
Phase
Not Applicable
Locations
Mexico
Study Type
Interventional
Intervention
Epinephrine
Sterile water
Indomethacin Rectal Suppository
Sponsored by
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pancreatitis, Acute focused on measuring pancreatitis after ERCP, epinephrine, papilla, rectal indomethacin

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18 years or older
  • Patient with an indication for endoscopic retrograde cholangiopancreatography
  • Patient without prior endoscopic retrograde cholangiopancreatography
  • Patient who accept contact by telephone

Exclusion Criteria:

  • Previous sphincterotomy
  • Allergy to epinephrine or indomethacin
  • NSAIDs use in the prior week
  • Pancreatic cancer located in the head
  • Chronic pancreatitis
  • Renal failure (Cr >1.4 mg / dl)
  • Indication for endotracheal intubation independent of endoscopic retrograde cholangiopancreatography
  • Biliodigestive derivation
  • Pregnant patients

Sites / Locations

  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Epinephrine sprayed on the papilla and rectal indomethacin

Sterile water sprayed on the papilla and rectal indomethacin

Arm Description

Epinephrine 1 mg/1 mL + 9 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure

10 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure

Outcomes

Primary Outcome Measures

Number of participants with pancreatitis after endoscopic retrograde cholangiopancreatography, used consensus definition
Consensus definition for post endoscopic retrograde cholangiopancreatography pancreatitis is: (1) new or worsened abdominal pain, (2) new or prolongation of hospitalization for at least 2 days, and (3) serum amylase or lipase 3 times or more the upper limit of normal, measured more than 24 hours after the procedure

Secondary Outcome Measures

Risk factors associated with the development of pancreatitis after endoscopic retrograde cholangiopancreatography assessed by relative risk

Full Information

First Posted
October 31, 2016
Last Updated
February 10, 2020
Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
search

1. Study Identification

Unique Protocol Identification Number
NCT02959112
Brief Title
Epinephrine Sprayed on the Papilla Versus Sterile Water Sprayed on the Papilla for Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography
Official Title
Epinephrine Sprayed on the Papilla and Rectal Indomethacin Versus Sterile Water Sprayed on the Papilla and Rectal Indomethacin for Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Prospective, Randomized, Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Terminated
Why Stopped
Because previous studies had found no difference, and one recent study even reported a higher incidence of PEP in treatment arm
Study Start Date
May 2016 (Actual)
Primary Completion Date
June 2019 (Actual)
Study Completion Date
June 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This multicentre randomised controlled trial included patients aged >18 years with an indication for ERCP and naive major papilla. All patients received 100 mg of rectal indomethacin and 10 ml of either sterile water or a 1:10,000 epinephrine dilution. Patients were asked about PEP symptoms via telephone 24 hours and 7 days after the procedure.
Detailed Description
This multicentre randomised placebo-controlled trial was conducted in two hospitals in Mexico: the National Institute of Medical Sciences and Nutrition "Salvador Zubirán" (INCMNSZ) in Mexico City, and Bernardette Hospital in Jalisco. The study was approved by both institutional review boards. All patients provided written informed consent. All patients were given a dose of rectal indomethacin (100 mg) at the beginning of the ERCP. Depending on the experimental group, either 10 ml of sterile water or 10 ml of a 1:10,000 epinephrine dilution (0.1 mg/ml) was sprayed on the ampulla through a biliary balloon or a sphincterotome, avoiding any direct contact with the papilla during irrigation at the end of the procedure. After the procedure, patients were monitored in the recovery room for 2 hours and then discharged. Symptoms of acute pancreatitis or any other complication were interrogated at baseline while in the recovery room, and then by telephone 24 hours and 7 days after the procedure. Serum levels of pancreatic enzymes were determined only if the patient developed abdominal pain after ERCP.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatitis, Acute
Keywords
pancreatitis after ERCP, epinephrine, papilla, rectal indomethacin

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants were allocated into groups by block randomisation using computed-generated numbers. The two groups were rectal indomethacin and epinephrine sprayed on the ampulla versus rectal indomethacin and sham water spray.
Masking
ParticipantCare ProviderOutcomes Assessor
Masking Description
As the two solutions are colourless, the endoscopist, nurse and patient were all blinded to the intervention. Investigators who participated in the evaluation of post-ERCP complications were also blinded to group allocation.
Allocation
Randomized
Enrollment
548 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Epinephrine sprayed on the papilla and rectal indomethacin
Arm Type
Active Comparator
Arm Description
Epinephrine 1 mg/1 mL + 9 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
Arm Title
Sterile water sprayed on the papilla and rectal indomethacin
Arm Type
Placebo Comparator
Arm Description
10 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
Intervention Type
Drug
Intervention Name(s)
Epinephrine
Intervention Type
Other
Intervention Name(s)
Sterile water
Intervention Type
Drug
Intervention Name(s)
Indomethacin Rectal Suppository
Primary Outcome Measure Information:
Title
Number of participants with pancreatitis after endoscopic retrograde cholangiopancreatography, used consensus definition
Description
Consensus definition for post endoscopic retrograde cholangiopancreatography pancreatitis is: (1) new or worsened abdominal pain, (2) new or prolongation of hospitalization for at least 2 days, and (3) serum amylase or lipase 3 times or more the upper limit of normal, measured more than 24 hours after the procedure
Time Frame
7 days
Secondary Outcome Measure Information:
Title
Risk factors associated with the development of pancreatitis after endoscopic retrograde cholangiopancreatography assessed by relative risk
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 years or older Patient with an indication for endoscopic retrograde cholangiopancreatography Patient without prior endoscopic retrograde cholangiopancreatography Patient who accept contact by telephone Exclusion Criteria: Previous sphincterotomy Allergy to epinephrine or indomethacin NSAIDs use in the prior week Pancreatic cancer located in the head Chronic pancreatitis Renal failure (Cr >1.4 mg / dl) Indication for endotracheal intubation independent of endoscopic retrograde cholangiopancreatography Biliodigestive derivation Pregnant patients
Facility Information:
Facility Name
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
City
Mexico City
State/Province
Tlalpan
ZIP/Postal Code
14000
Country
Mexico

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33558263
Citation
Romano-Munive AF, Garcia-Correa JJ, Garcia-Contreras LF, Ramirez-Garcia J, Uscanga L, Barbero-Becerra VJ, Moctezuma-Velazquez C, Ochoa-Rubi JA, Toledo-Cuque J, Vazquez-Anaya G, Keil-Rios D, Grajales-Figueroa G, Ramirez-Luna MA, Valdovinos-Andraca F, Zamora-Nava LE, Tellez-Avila F. Can topical epinephrine application to the papilla prevent pancreatitis after endoscopic retrograde cholangiopancreatography? Results from a double blind, multicentre, placebo controlled, randomised clinical trial. BMJ Open Gastroenterol. 2021 Feb;8(1):e000562. doi: 10.1136/bmjgast-2020-000562.
Results Reference
derived

Learn more about this trial

Epinephrine Sprayed on the Papilla Versus Sterile Water Sprayed on the Papilla for Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography

We'll reach out to this number within 24 hrs